IL2 and adenocarcinoma: The huKS-IL2 IC improves NK-tumor cell conjugation by exclusively targeting the EpCAM antigen expressed in lung, ovary, colon, and other adenocarcinomas (Buhtoiarov et al. 2011; Connor et al. 2004; Kim et al. 2009).